InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,713.64
(
1.70%
)
US TECH 100
19,334.40
(
0.00%
)
Dow Jones
42,025.19
(
1.26%
)
Brent Oil
73.95
(
-0.50%
)
Bitcoin
63,538.82
(
0.94%
)
Post# of 3329
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

fsulevine

Send PM Follow Ignore
Followers 10
Posts 2165
Boards Moderated 0
Alias Born 05/15/2015

fsulevine

Re: None

Wednesday, 04/19/2017 10:54:21 PM

Wednesday, April 19, 2017 10:54:21 PM

Post# of 3329
Once approved for CKD in non/pre-dialysis patients, what are the chances of a buyout? Going it alone is pretty tough for a small company, but certainly not impossible (see Amarin and the growth of Vascepa, which still has a long way to go and much upside potential still). I think looking for a buyout in the $18-$23 range might be the best for Keryx. What do you all think?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up